BioMedNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD) Reports on Publication of Low-Dose Suramin for ASD Research

PaxMedica (NASDAQ: PXMD), a clinical-stage biopharmaceutical company, announced that its groundbreaking research will be published in the “Annals of General Psychiatry,” an internationally recognized scientific psychiatry publication. The research was reported in a manuscript titled “Randomized clinical trial of low-dose suramin intravenous infusions for treatment of autism spectrum disorder,” which will be published by the psychiatry publication. Written by PaxMedica chief medical officer Dr. David Hough, MD, along with nine coauthors, the article reports on the potential of monthly suramin intravenous infusions as a safe and potentially efficacious treatment for the core symptoms of autism spectrum disorder (“ASD”). Coauthors of the article include Alice Mao, MD; Michael Aman, PhD; Reymundo Lozano, MD, MS; Constance Smith-Hicks, MD, PhD; Veronica Martinez-Cerdeno, PhD; Michael Derby; Zachary Rome; Miel Malan, MD; and Robert Findling, MD. An open access journal emphasizing a biopsychosocial approach to illness and health, the “Annals of General Psychiatry” supports the principles of evidence-based medicine, further validating the significance of this research. “The acceptance of this manuscript represents a significant milestone in PaxMedica’s continued dedication to pioneering innovative treatments for autism spectrum disorder,” said PaxMedia chief medical officer Dr. David Hough in the press release. “We are honored to contribute to the field of psychiatry with this significant research, underscoring our commitment to advancing the understanding and treatment of ASD.”

To view the full press release, visit https://ibn.fm/DLvhG

About PaxMedica Inc.

PaxMedica is a forward-looking, clinical-stage biopharmaceutical firm specializing in cutting-edge, anti-purinergic drug therapies (“APT”) designed to address challenging neurologic disorders. Its scope encompasses a spectrum of conditions, from neurodevelopmental disorders, including autism spectrum disorder (“ASD”) to the debilitating myalgic encephalomyelitis/chronic fatigue syndrome (“ME/CFS”), marked by both physical and cognitive burdens. PaxMedica prioritizes the advancement and evaluation of its flagship program, PAX-101 — an intravenous suramin formulation — primarily focused on ASD treatment, while also broadening clinical insights into its potential applications for conditions such as ME/CFS. For more information about the company, visit www.PaxMedica.com.

NOTE TO INVESTORS: The latest news and updates relating to PXMD are available in the company’s newsroom at https://ibn.fm/PXMD

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.